Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a specialty pharmaceutical company that focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company’s product candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. For more information, visit the company’s website at www.zynerba.com.
About HempWire
HempWire (HW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, HW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information, visit https://www.hempwire.com
Please see full disclaimers on the HempWire website: http://nnw.fm/Disclaimer
HempWire (HW)
Denver, CO
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
Legislators in states across the country are working towards strictly regulating and/or banning intoxicating hemp…
A proposal introduced by Sen. Colleen Burton that would ban delta-8 THC hemp products is…
California recently extended a ban on intoxicating hemp products with THC that was set to…
A new poll has determined that frequent consumers of marijuana like using delivery platforms to…
The demand for plant-based proteins has increased in the last couple of years as consumer…
The CBD market in the United Kingdom has grown since the compound’s extracts were designated…